Benefits of Early ASCT for Newly Diagnosed Multiple Myeloma (MM) and the Incidence of Second Primary Cancer with Lenalidomide Maintenance in the Treatment of MM


Benefits of Early ASCT for Newly Diagnosed Multiple Myeloma (MM) and the Incidence of Second Primary Cancer with Lenalidomide Maintenance in the Treatment of MM
Slides from presentations at ASCO 2011 and comments from Sergio Giralt, MD

Palumbo AP et al. Incidence of second primary malignancy (SPM) in melphalan-prednisone-lenalidomide combination followed by lenalidomide maintenance (MPR-R) in newly diagnosed multiple myeloma patients (pts) age 65 or older. Proc ASCO 2011;Abstract 8007.

Dr Giralt is Chief of the Adult Bone Marrow Transplant Service at Memorial Sloan-Kettering Cancer Center in New York, New York.